Author: keesto

A new study finds that women diagnosed with pre-cancerous cervical conditions after they get the human papillomavirus (HPV) vaccine can still benefit from the shot because it cuts their risk of future HPV-related cervical disease.

On May 15, 2012 a 17 member federal advisory committee unanimously voted to recommend that the FDA approve OraSure Technologies Inc.’s OraQuick In-Home HIV Test citing that the accessibility factor of the test outweighs the risks of false results.